Full-Time

Associate Process Development

Bioprinting

Aspect Biosystems

Aspect Biosystems

51-200 employees

Bioprints allogeneic tissue therapeutics

Compensation Overview

CA$64k - CA$72k/yr

+ Equity

Vancouver, BC, Canada

In Person

Bachelor's, Master's

Category
Biology & Biotech (1)
Required Skills
GMP
Biochemistry
Data Analysis

Get referred to Aspect Biosystems

See people who can refer or advise you

Requirements
  • A master's degree in biomedical engineering, materials science, biochemistry, life sciences, or a related field, or a bachelor's degree with 1–2 years of industry experience.
  • Familiarity with biomanufacturing process development, including scale-up and optimization.
  • Basic understanding of Good Manufacturing Practices and Good Documentation Practices, with experience working in regulated environments.
  • Experience in a current Good Manufacturing Practice setting, especially in cell therapy, is beneficial.
  • Ability to collaborate in a multidisciplinary team environment.
  • Ability to communicate effectively with different audiences in diverse situations.
Responsibilities
  • Support the in-vitro and in-vivo manufacturing of bioprinted tissue therapeutics for Good Manufacturing Practices and research and development goals.
  • Prepare materials and reagents for bioprinted tissue therapeutic processes in compliance with Good Documentation Practices.
  • Help carry out process optimization and scale-up activities to support investigational new drug-enabling work for multiple bioprinted tissue therapeutic product candidates.
  • Perform routine maintenance of bioprinting equipment to support consistent production.
  • Assist in developing and testing bioprinting processes and bioprinted tissue therapeutics to meet project goals.
  • Follow standard operating procedures and collaborate with process development teams to ensure compliance.
  • Ensure optimization and scaling strategies comply with current Good Manufacturing Practice regulations.
  • Work with research and development, chemistry, manufacturing and controls, quality, and regulatory teams to support Bioprinting Design Transfers in compliance with regulatory requirements.
  • Design and execute studies to qualify and characterize new bioprinted tissue therapeutics.
  • Perform data collection and analysis to contribute insights for process improvement.
  • Collaborate cross-functionally to help develop and refine bioprinting methods for different therapeutic applications.
  • Create and follow experimental forms, standard operating procedures, batch production records, and other documentation as needed.
Desired Qualifications
  • Experience in a current Good Manufacturing Practice setting, especially in cell therapy.

Aspect Biosystems develops bioprinted tissue therapeutics for regenerative medicine. Its work centers on a platform that combines proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design to create allogeneic tissue therapeutics for clinical use. The company works through strategic collaborations with leading pharmaceutical and biotechnology firms, funded by partnerships and investors. The product approach uses bioprinting to assemble tissue constructs layer by layer from cells and biomaterials, guided by computational design, producing off-the-shelf (allogeneic) tissue therapies. What sets the company apart is its integrated platform, a focus on allogeneic, scalable tissue products, and a collaboration-driven business model with strong industry partnerships, backed by a solid funding base. Its goal is to advance regenerative medicine by delivering a targeted pipeline of bioprinted tissue therapeutics through collaborations and continued investment.

Company Size

51-200

Company Stage

Grant

Total Funding

$352.7M

Headquarters

Vancouver, Canada

Founded

2013

Get referred to Aspect Biosystems

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • 2026-04-02: Canada added C$79 million to Aspect’s C$280 million development program.
  • 2025-01-08: Aspect raised US$115 million Series B from Dimension, Novo Nordisk, and others.
  • Headcount reached roughly 154 in March 2026, showing continued scale despite slower hiring.

What critics are saying

  • Clinical translation from bioprinted tissues to humans remains unproven before 2031.
  • Novo Nordisk’s 2026 retreat from cell therapy makes Aspect dependent on one shaky champion.
  • If pancreatic implants fail in humans, Aspect’s platform loses its lead program and valuation anchor.

What makes Aspect Biosystems unique

  • 2026-01-20: Aspect controls Novo Nordisk’s stem-cell islet and hypoimmune technologies.
  • Aspect’s proprietary bioprinting combines cells, biomaterials, and AI design into implantable tissue.
  • Canada backs Aspect’s Vancouver GMP biomanufacturing buildout, strengthening domestic manufacturing moats.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

0%

2 year growth

0%
VoxelMatters
Jul 24th, 2026
Aspect Biosystems expanding cellular medicine work with $79 million government funding

Discover how Aspect Biosystems is advancing with a $79 million investment to boost its bioengineered cellular medicines project.

Business Examiner
Jul 24th, 2026
Aspect Biosystems lands $2.6B Novo Nordisk deal to develop cellular diabetes treatment

Vancouver's Aspect Biosystems has secured over $500 million in total investment and entered a $2.6-billion partnership with Danish pharmaceutical giant Novo Nordisk to develop cellular treatments for Type 1 diabetes. The company, founded in 2013 from University of British Columbia research, now employs 130 people. Aspect uses AI-assisted bioprinting technology to create living human tissue that can detect glucose levels and release insulin accordingly. The bioprinted cells are engineered to evade immune rejection once implanted. In April, the federal government announced a $280-million partnership to accelerate clinical development and strengthen biomanufacturing capacity. The British Columbia government had previously committed $23.8 million in 2024. The company is now focused on translating its bioprinting platform from laboratory production into clinical use.

VentureLabs
Apr 9th, 2026
Canadian government supports SFU VentureLabs Alumni, Aspect Biosystems with $79 Million in funding.

Canadian government supports SFU VentureLabs Alumni, Aspect Biosystems with $79 Million in funding. On April 2nd, the Government of Canada announced an investment of $79 Million for SFU VentureLabs Alumni, Aspect Biosystems. This initiative was conducted through the Strategic Response Fund (SRF), a fund focused on supporting Canadian industries' innovation, adaptation and competition in an evolving global economy. The Province of British Columbia will also be supporting Aspect Biosystems with $23.8 million to expand the company. The national government is strengthening its partnership with Aspect Biosystems with an additional $280 million collaboration that supports the scaling of Aspect's clinical development, enhances their AI-platform and accelerates the commercialization process. This installation will create upwards of 400 jobs for employees and co-op students alike. Aspect Biosystems' CEO, Tamer Mohammed remains enthusiastic about this joint effort. "With this investment and the deepening of our partnership with the Government of Canada, we are taking a major step toward building a generational company anchored in Canada and delivering life-changing therapies to patients around the world.", said Mohammed Tamer, CEO of Aspect Biosystems

Pharmaceutical Technology
Apr 6th, 2026
Aspect Biosystems receives funding for cellular medicine project.

Aspect Biosystems receives funding for cellular medicine project. The investment adds to the C$200m co-investment announced with Canada and British Columbia in 2024. Aspect Biosystems has secured a C$79m($56.6m) investment from the Government of Canada to support a C$280m multi-year project aimed at advancing its pipeline of bioengineered cellular medicines for endocrine and metabolic diseases. The project will enhance Aspect Biosystems' clinical development capabilities and bolster its integrated platform for developing and manufacturing advanced cellular medicines. The investment is in addition to the C$200m co-investment previously announced with the Government of Canada and Province of British Columbia in 2024. Aspect Biosystems focuses on developing therapies intended to restore or supplement biological functions and deliver functional cures for complex, hard-to-treat diseases. The pipeline leverages a platform that integrates proprietary AI-based bioprinting and hypoimmune cell engineering for creating immune-evasive cellular medicines. The partnership announcement took place at Aspect Biosystems' Vancouver headquarters with Canada Minister of Industry and Minister responsible for Economic Development for Quebec Mélanie Joly in attendance. Aspect Biosystems CEO Tamer Mohamed said: "This investment from the Government of Canada is a powerful vote of confidence and adds to the significant momentum at Aspect as Pharmaceutical Technology advance its bioengineered cellular medicines towards patient impact. "Pharmaceutical Technology has built a truly world-class team with deep cell therapy development expertise and recently entered a new phase of its partnership with Novo Nordisk to develop curative medicines for diabetes, integrating key stem cell and hypoimmune cell engineering technologies under Aspect's leadership. "With this investment and the deepening of our partnership with the Government of Canada, we are taking a major step toward building a generational company anchored in Canada and delivering life-changing therapies to patients around the world." Earlier this year, Novo Nordisk and Aspect Biosystems commenced a new phase in their ongoing partnership focused on curative cellular medicines to treat diabetes. Give your business an edge with its leading industry insights.

BetaKit
Apr 2nd, 2026
Aspect Biosystems gets $79M from feds for $280M 3D-printed tissue treatment project

Vancouver-based Aspect Biosystems has received $79 million from Canada's Strategic Response Fund to support a $280-million project developing 3D-printed human tissue treatments. The company will contribute the remaining $201 million. Founded in 2013 as a University of British Columbia spinout, Aspect bioprints tissue implants using living stem cells and hydrogel polymers to potentially repair organs like the pancreas in Type 1 diabetes patients. The funding will enhance clinical development capabilities and scale biomanufacturing for advanced cellular medicines. This follows previous government support, including $49 million federally and nearly $24 million from British Columbia in July 2024. Aspect raised $115 million USD in Series B funding in January 2025 and partners with Danish pharmaceutical giant Novo Nordisk on tissue therapy development.